Fig. 7: In vivo efficacy of LY2874455 as a single agent and in combination with standard-of-care for treatment of SCLC.
From: Targeting PEA3 transcription factors to mitigate small cell lung cancer progression
A Experimental scheme for in vivo evaluation of single agent LY2874455 in H526 xenograft model. B H526 xenograft tumor growth comparing daily intraperitoneal administration of 12 mg/kg LY2874455 (n = 10) compared to vehicle (n = 10). Error bars represent standard error of the mean. C Representative photograph of tumors at 14 days of treatment. D Experimental scheme for evaluation of LY2874455 in combination with cisplatin and etoposide. E H526 xenograft tumor growth comparing daily intraperitoneal administration of 12 mg/kg LY2874455 in combination with cisplatin and etoposide (n = 6) compared to only cisplatin and etoposide (n = 7). Error bars represent standard error of the mean. F Representative photograph of tumors at 28 days of treatment. CE = cisplatin and etoposide. G Representative images of hematoxylin and eosin stained sections.
